Optinose
Total Raised
$120.58MInvestors Count
8Deal Terms
3Funding, Valuation & Revenue
9 Fundings
Optinose has raised $120.58M over 9 rounds.
Optinose's latest funding round was a Take Private for on May 21, 2025.
Optinose's valuation in October 2017 was $566.18M.
Optinose's latest post-money valuation is from May 2025.
Sign up for a free demo to see Optinose's valuations in May 2025 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
5/21/2025 | Take Private | 6 | ||||
10/12/2017 | IPO | $566.18M | ||||
4/7/2017 | Series E | |||||
10/6/2015 | Series D | |||||
8/4/2014 | Series C - II |
Date | 5/21/2025 | 10/12/2017 | 4/7/2017 | 10/6/2015 | 8/4/2014 |
|---|---|---|---|---|---|
Round | Take Private | IPO | Series E | Series D | Series C - II |
Amount | |||||
Investors | |||||
Valuation | $566.18M | ||||
Revenue | |||||
Sources | 6 |
Optinose Deal Terms
3 Deal Terms
Optinose's deal structure is available for 3 funding rounds, including their Take Private from May 21, 2025.
Round | Take Private | IPO | Series A |
|---|---|---|---|
Funding Date | |||
Pre-Money Valuation | |||
Post-Money Valuation | |||
Amount Raised | |||
Shares Authorized | |||
Issuance Price | |||
Dividend Rate | |||
Liquidation Preferences | |||
Liquidation Price | |||
Participation | |||
Conversion Price | |||
Anti Dilution | |||
General Voting | |||
Board Voting | |||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Take Private | |||||||||||||||
IPO | |||||||||||||||
Series A |
Optinose Investors
8 Investors
Optinose has 8 investors. Paratek Pharmaceuticals invested in Optinose's Take Private funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
5/21/2025 | 5/21/2025 | 1 Take Private | Corporation | Massachusetts | ||
Private Equity | New York | |||||
Venture Capital | United Kingdom | |||||
Venture Capital | New York | |||||
Investment Bank | Massachusetts |
First funding | 5/21/2025 | ||||
|---|---|---|---|---|---|
Last Funding | 5/21/2025 | ||||
Investor | |||||
Rounds | 1 Take Private | ||||
Board Seats | |||||
Type | Corporation | Private Equity | Venture Capital | Venture Capital | Investment Bank |
Location | Massachusetts | New York | United Kingdom | New York | Massachusetts |
Compare Optinose to Competitors
FORMAC Pharmaceuticals N.V. is a company engaged in the pharmaceutical industry. The company specializes in silica-based drug delivery platforms intended to improve the performance of poorly soluble drugs. FORMAC Pharmaceuticals collaborates with pharmaceutical and animal health companies. It was founded in 2007 and is based in Belgium.
Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.
Pulse NeedleFree Systems is a medical technology company focused on development of needle-free pharmaceutical injection systems for the animal health and human health industries. Pulse's animal health injection systems are marketed to large livestock producers in the United States and select international markets.
Imagine Pharmaceuticals is developing technology to facilitate delivery of drugs to the brain
Travanti Pharma is a medical device company specializing in the development and sale of microneedle array products for the healthcare sector. Their main offering includes the AdminPen2 hollow microneedle injection device, designed for self-administrable drug delivery without the need for reformulating existing drug formulations. The company primarily serves sectors that require drug delivery solutions, such as oncology, immunology, and transdermal therapy. It was founded in 1997 and is based in Mendota Heights, Minnesota.

Next Breath is involved in the development and analytical testing of inhalation and nasal drug products within the pharmaceutical industry. The company provides services including pharmaceutical formulation, CMC testing, finished batch release, post-approval stability, and regulatory submissions support. Next Breath serves pharmaceutical, biotech, and medical device companies with a focus on inhalation and nasal delivery systems. It is based in Baltimore, Maryland.
Loading...

